Interconversion and tissue distribution of pentoxifylline and lisofylline in mice

Chirality

Volumn 18, Issue 8, 2006, Pages 644-651

  Wyska, Elzbieta ^a   Pȩkala, Elzbieta ^a   Szymura Oleksiak, Joanna ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Enantioselective disposition; Interconversion clearance, tissue to serum AUC ratio; Pharmacokinetic model

Indexed keywords

LISOFYLLINE; PENTOXIFYLLINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHIRAL CHROMATOGRAPHY; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG LIVER LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; LUNG; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; REACTION ANALYSIS; REACTION TIME; TISSUE DISTRIBUTION;

ANIMALS; AREA UNDER CURVE; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HEMATOLOGIC AGENTS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED STRAINS; PENTOXIFYLLINE; REPRODUCIBILITY OF RESULTS; STEREOISOMERISM; TISSUE DISTRIBUTION;

EID: 33750060076     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20299     Document Type: Article

References (24)

1. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch III JP, Larrick J, Kunkel SL. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988;155:1230-1260.
2. Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-α) biosynthesis in alveolar epithelial cells. J Pharmacol Exp Ther 2002;300:559-566.
3. Noel PS, Nelson R, Bokulic G, Bagby H, Lippton G, Lipscomb G, Summer W. Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality. Life Sci 1990;47:1023-1029.
4. Zeni F, Pain P, Vindimian M, Gay JP, Gery P, Bertrand M, Page Y, Page D, Vermesch R, Bertrand JC. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. Crit Care Med 1996;24:207-214.
5. Lauterbach R, Pawlik D, Kowalczyk D, Ksyciński W, Helwich E, Zembala M. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit Care Med 1999;27:807-814.
6. Ambrus JL, Stadler S, Kulaylat M. Hemorrheologic effects of metabolites of pentoxifylline (Trental). J Med 1995;26:65-75.
7. Cottam HB, Shih H, Tehrani LR, Wasson DB, Carson DA. Substituted xanthines, pteridinediones, and related compounds as potential anti-inflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor α. J Med Chem 1996;39:2-9.
8. Rice GC, Brown PA, Nelson RJ, Bianco JA, Singer JW, Bursten S. Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc Natl Acad Sci 1994;91:3857-3861.
9. Yang Z, Chen M, Nadler JL. Lisofylline: a potential lead for the treatment of diabetes. Biochem Pharm 2005;69:1-5.
10. Van Amersfoort ES, Van Berkel TJC, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 2003;16:379-414.
11. Lillibridge JA, Kalhorn TF, Slattery JT. Metabolism of lisofylline and pentoxifylline in human liver microsomes and cytosol. Drug Metab Dis 1996;24:1174-1179.
12. nd ed. Stockholm: Swedish Pharmaceutical Press; 1997. p 770.
13. Miller K, Louie A, Baltch AL, Smith RP, Davis PJ, Gordon MA. Pharmacokinetics of pentoxifylline and its metabolites in healthy mice and in mice infected with Candida albicans. Antimicrob Agents Chemother 1998;42:2405-2409.
14. Luke DR, Rocci ML, Hoholick C. Inhibition of pentoxifylline clearance by cimetidine. J Pharm Sci 1986;75:155-157.
15. Hinze HJ. Zur Pharmakokinetik von 3,7-Dimethyl-1-(5-oxo-hexyl)-xanthin (BL 191) am Menschen. Arzneim-Forsch 1972;22:1492-1495.
16. Beermann B, Ings R, Mansby J, Chamberlain J, McDonald A. Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin Pharmacol Ther 1985;37:25-28.
17. Bursten SL, Federighi D, Wald J, Meengs B, Spickler W, Nudelman E. Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids. J Pharmacol Exp Ther 1998;284:337-345.
18. Smith RV, Waller ES, Doluisio JT, Bauza MT, Puri SK, Ho I, Lassman HB. Pharmacokinetics of orally administered pentoxifylline in humans. J Pharm Sci 1986;75:47-52.
19. Nicklasson M, Björkman S, Roth B, Jönsson M, Hoglund P. Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. Chirality 2002;14:643-652.
20. Rames A, Poirier J-M, LeCoz F, Midavaine M, Lecocq B, Grange J-D, Poupon R, Cheymol G, Jaillon P. Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. Clin Pharmacol Ther 1990;47:354-359.
21. Hinze HJ, Grigoleit HG, Rethy B. Bioavailability and pharmacokinetics of pentoxifylline from Trental 400' in man. Pharmatherapeutica 1976;1:160-171.
22. Matsura K, Hara A, Sawada H, Bunai Y, Ohya I. Localization of pulmonary carbonyl reductase in guinea pig and mouse: enzyme histochemical and immunohistochemical studies. J Histochem Cytochem 1990;38:217-223.
23. Freise H, Bruckner UB, Spiegel HU. Animal models of sepsis. J Invest Surg 2001;14:195-212.
24. Van Furth AM, Verhard-Seijmonsbergen EM, Van Furth R, Langermans JAM. Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-α, IL-1β and IL-10 by human leucocytes. Immunology 1997;91:193-196.